CoreMedic GmbH
Radolfzell Am Bodensee · Founded 2012
About CoreMedic GmbH
CoreMedic was initiated in 2012 as a spin-out of the Heart Center of University of Bern, Switzerland, in order to develop an innovative treatment concept for mitral valve regurgitation (MR). The initiators of CoreMedic had a simple but challenging idea: to combine the least invasive treatment option for MR, replacement of mitral chords, and the least invasive operational procedure into one new system: ChordArt. In 2017, the development of ChordArt had progressed towards first use in a human trial, enabling CoreMedic to attract institutional financing. The company moved to RIZ-innovation center at Radolfzell, Germany, located at Lake Constance close to the Swiss border within the leading medical technology cluster of Tuttlingen, Germany. Following successful conclusion of the first human trial of ChordArt in 2018, and two-year data confirming the powerful treatment effect of the ChordArt implant in patients with severe MR, CoreMedic GmbH is tirelessly working to make the ChordArt TMVr system available to patients.
Company Facts
- Founded: 2012
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2025)
- Website: coremedic.de
- Phone: +49 7732 893 4610
Social Profiles
Canonical: https://fsome.com/organization/coremedic-gmbh-8261585 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.